TOKYO, Japan & MUNICH, Germany--(BUSINESS WIRE)--Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the European Medicines Agency (EMA) has validated the Type II ...
If approved, AQNEURSA would become the first approved therapy for Ataxia-Telangiectasia in the European Economic Area IntraBio Inc. today announced the submission of a variation application to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results